Patent SG-11201809041T-A (SG)
Title: Compositions and methods for selective protein expression
Inventor: GOLOSOV ANDREI
IPC: C12N15/62
Filed: 2017-04-14
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101111110101 0111110111110111 OM International Bureau 0.. .... .. (10) International Publication Number ..... ..or::,,, (43) International Publication Date WO 2017/181119 A2 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/725 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/027778 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: 14 April 2017 (14.04.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/322,931 15 April 2016 (15.04.2016) US 62/481,094 3 April 2017 (03.04.2017) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: NOVARTIS AG [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH). THE TRUSTEES OF THE UNI- VERSITY OF PENNSYLVANIA [US/US]; 3160 Chest- nut Street, Suite 200, Philadelphia, PA 19104 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors; and (71) Applicants (for US only): GOLOSOV, Andrei [ /US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Novartis Institutes for BioMedical Reseach, Inc., 100 GW, KM, ML, MR, NE, SN, TD, TG). Technology Square, Cambridge, MA 02139 (US). Declarations under Rule 4.17: — _ GUIMARAES, Carla [PT/US]; Novartis Institutes for BioMedical Reseach, Inc., 100 Technology Square, Cam- — as to applicant's entitlement to apply for and be granted a _ bridge, MA 02139 (US). MOTZ, Gregory [US/US]; 83 4.17(ii)) patent (Rule Greene St., Quincy, MA 02170 (US). MILONE, Michael — as to the applicant's entitlement to claim the priority of the = [US/US]; 314 Surrey Road, Cherry Hill, NJ 08002 (US). earlier application (Rule 4.17(iii)) — ELLEBRECHT, Christoph, T. [DE/US]; 415 S. 13th Street, Philadelphia, PA 19147 (US). PAYNE, Aimee, S. Published: = — [US/US]; 536 Hamilton Road, Merion Station, PA 19066 — without international search report and to be republished = (US). upon receipt of that report (Rule 48.2(g)) = Agents: COLLAZO, Diana, M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, (74) — with sequence listing part of description (Rule 5.2(a)) — = Cambridge, MA 02142 (US). — = = = = = = ei C:7 Il Il Il of (54) Title: COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION 1-1 ----- (57) : Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage I N I-1 site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential ele - C ments: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the N two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by en. ) targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is select- ively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T 5 cell are also described herein.